Contributions
Abstract: P605
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Microvesicles (MVs) have been indicated as important mediators of intercellular communication and are emerging as new biomarkers of reactive microglia. We present the first exploratory study on the prognostic role of CSF MVs in patients with a clinically isolated syndrome (CIS).
Methods: We investigated CSF MVs levels in 50 patients with CIS with a short conversion interval to McDonald 2010 multiple sclerosis (MS) (fast converters (FC), conversion time < 1 year); 51 patients with non-converting CIS (non-converters (NC), follow-up: 3.5 years (1.3-5.9)); and 50 controls.
Results: MVs levels were higher in FC (855 per ml (415-2407)) than in NC (423 per ml (235-1010)) and in controls (320 per ml (215-542)) (OR=2.38; 95% CI 1.19 to 5.32; p=0.023 and OR= 6.41; 95% CI 1.38 to 41.5; p=0.03 respectively). The results did not change after adjustment for covariates of MS risk (MRI T2 lesions and gadolinium enhancing lesions, CSF oligoclonal bands, EDSS). When grouping FC and NC, increased CSF MVs concentration was significantly associated with increasing numbers of gadolinium-enhancing lesions (OR=2.07; 95% CI 1.02 to 4.63; p=0.05) at CIS diagnosis. The prognostic value of CSF MVs levels was particularly evident in patients with active lesions (OR=3.29; 95% CI 1.37 to 5.64).
Conclusions: If replicated in future studies, CSF MVs may represent a reliable biomarker of microglial activation and prognostic factor in CIS and MS.
Disclosure: V.M. has received personal compensation for activities with Biogen, Merck
Serono, Bayer Schering, TEVA and Sanofi as a speaker. G.C.has received compensation for consulting services and/or speaking activities from Bayer Schering, Serono, Merck Serono, Teva, Sanofi and Biogen. G.D.C, T.C., A.F., F.S., L.M., B.C., G.C., R.F. report no discosures.
Abstract: P605
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Microvesicles (MVs) have been indicated as important mediators of intercellular communication and are emerging as new biomarkers of reactive microglia. We present the first exploratory study on the prognostic role of CSF MVs in patients with a clinically isolated syndrome (CIS).
Methods: We investigated CSF MVs levels in 50 patients with CIS with a short conversion interval to McDonald 2010 multiple sclerosis (MS) (fast converters (FC), conversion time < 1 year); 51 patients with non-converting CIS (non-converters (NC), follow-up: 3.5 years (1.3-5.9)); and 50 controls.
Results: MVs levels were higher in FC (855 per ml (415-2407)) than in NC (423 per ml (235-1010)) and in controls (320 per ml (215-542)) (OR=2.38; 95% CI 1.19 to 5.32; p=0.023 and OR= 6.41; 95% CI 1.38 to 41.5; p=0.03 respectively). The results did not change after adjustment for covariates of MS risk (MRI T2 lesions and gadolinium enhancing lesions, CSF oligoclonal bands, EDSS). When grouping FC and NC, increased CSF MVs concentration was significantly associated with increasing numbers of gadolinium-enhancing lesions (OR=2.07; 95% CI 1.02 to 4.63; p=0.05) at CIS diagnosis. The prognostic value of CSF MVs levels was particularly evident in patients with active lesions (OR=3.29; 95% CI 1.37 to 5.64).
Conclusions: If replicated in future studies, CSF MVs may represent a reliable biomarker of microglial activation and prognostic factor in CIS and MS.
Disclosure: V.M. has received personal compensation for activities with Biogen, Merck
Serono, Bayer Schering, TEVA and Sanofi as a speaker. G.C.has received compensation for consulting services and/or speaking activities from Bayer Schering, Serono, Merck Serono, Teva, Sanofi and Biogen. G.D.C, T.C., A.F., F.S., L.M., B.C., G.C., R.F. report no discosures.